title: DEP domain containing 1 is a novel diagnostic marker and prognostic predictor for hepatocellular carcinoma.
abstract: BACKGROUND
  This study was conducted to determine DEPDC1 expression in hepatocelluar carcinomas (HCCs) and to reveal its potential role in diagnosis and prognosis of affected patients.
  
  
  METHODS
  DEPDC1 expression at the mRNA level was detected by quantitative real-time PCR (qRT-PCR) in 205 cases of HCC and paired adjacent normal liver tissues, and by semi-quantitative RT-PCR in 20 cases. Survival curves were obtained by using Kaplan-Meier method and Log-rank test. Independent predictors associated with regard to disease free survival (DFS) and overall survival (OS) were identified using the Cox proportional hazard model.
  
  
  RESULTS
  High DEPDC1 mRNA levels were detected in 144 out of 205 cases (70.24%) of HCC, significantly associated with clinicopathological parameters, including tumor size (≥4cm), alpha-fetoprotein (≥100ng/ml), B-C of BCLC stage and recurrence. Kaplan-Meier survival analysis revealed that HCC patients with high DEPDC1 expression had poor OS and DFS. Multivariate analysis demonstrated that high DEPDC1 expression was an independent predictor of OS (HR=1.651; 95% 95%CI, 1.041- 2.617; p=0.033) and DFS (HR=1.583; 95%CI, 1.01- 2.483; p=0.045).
  
  
  CONCLUSIONS
  Our results indicate DEPDC1 might be a novel diagnostic marker and an independent prognostic predictor for HCC patients.
authors.affiliation: Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China E-mail : hgjj@163.com, gxlzzq@163.com.
authors.forename: Sheng-Guang
authors.initials: SG
authors.lastname: Yuan
authors.forename: Wei-Jia
authors.initials: WJ
authors.lastname: Liao
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Yang
authors.forename: Guo-Jin
authors.initials: GJ
authors.lastname: Huang
authors.forename: Zhao-Quan
authors.initials: ZQ
authors.lastname: Huang
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D020690:GTPase-Activating Proteins / Q000235:genetics*; D006801:Humans; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; C584411:DEPDC1 protein, human; D020690:GTPase-Activating Proteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D000509:alpha-Fetoproteins